tirzepatide clinical trial shows additional 21.1% weight loss following intensive lifestyle intervention Tirzepatide after intensive lifestyle intervention

Statements Author contributions YaH: Conceptualization, Writing original draft, Writing review & editing

"Market challenges were the reason cited for the recently announced departure of Novo's CEO, Lars Fruergaard Jrgensen, as the company now searches for his successor.

If the medication is used solely for weight loss, standard Indian health insurance policies do not cover the cost

These developments are consistent with the evolving understanding of the gastrointestinal tract as a key endocrine organ that regulates appetite, glucose homeostasis, energy expenditure, and gastrointestinal motility through a complex network of hormonal signals [20]